SYMTUZA (Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate) Patent Expiration, LOE Window & CMS Spending

SYMTUZA (Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate) by Johnson & Johnson: FDA Orange Book core substance LOE 2032-10-06 (last listed 2038-07-19), 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN210455 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2032-10-06
Last Listed Patent or Exclusivity Date2038-07-19
Orange Book Patents (*PED Extensions)13 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.